IN TODAY’S EDITION
  • 📈 | Microdosing goes mainstream
  • ⛽️ | Waste into fuel
  • ☕️ | Lion’s mane coffee

Hi Shroomers. Psilocybin mushrooms will speed up meeting God, and functional mushrooms will slow it down.

A reader wrote in: “Need more practical info with products available now on market, not at research farms in Mongolia.” This is fair. I’ve spent the last three years summarizing studies and staying neutral, and neutral is starting to feel like a disservice. You came here for mushrooms you can actually use, so it’s time I tell you what I think, what I actually buy, and what’s marketing dressed up as medicine. The Shroom Scan is changing form. More on that soon. For now, here’s the research.

HEALTH & WELLNESS

Cholesterol absorption shift 🫀 Oyster mushroom (Pleurotus ostreatus) powder providing 3 g of daily β-glucans lowered several markers tied to how much cholesterol the body absorbs, especially in women after 4 weeks. In the 46-person trial, adults took 8.4 g of mushroom powder daily and showed drops in compounds linked to cholesterol uptake in the gut, even though LDL cholesterol itself did not significantly change. Every participant taking the mushroom powder also showed measurable ergosterol in their blood averaging 21 µg/mL, confirming the mushroom compounds were actively absorbed by the body.

Gut fuel fungi 🦠 Edible mushrooms contain β-glucans, chitin, polyphenols, and trehalose that resist digestion and feed gut microbes, increasing short-chain fatty acids like acetate, propionate, and butyrate. These metabolites support intestinal barrier strength, immune balance, inflammation control, and metabolic health through everyday foods like shiitake (Lentinula edodes), reishi (Ganoderma lucidum), lion’s mane (Hericium erinaceus), and cordyceps (Cordyceps militaris). The biggest gap is human data, since most evidence still comes from in vitro and animal research, but the gut-health pathway is one of the strongest functional mushroom angles.

Reishi clinical push 🥼 Reishi (Ganoderma lucidum) contains polysaccharides, triterpenoids, sterols, and phenolic compounds tied to immune signaling, inflammation control, antioxidant defense, liver protection, and anticancer pathways, with research now expanding into drug delivery systems, antimicrobial nanomaterials, and functional foods. Scientists are also developing reishi-based nanoparticles and biosensors while exploring applications in skin health, anti-aging products, and metabolic support, signaling a shift from traditional remedy toward pharmaceutical and biotech integration. The review highlights one of the clearest examples of a medicinal mushroom moving beyond vague wellness positioning into clinically targeted therapeutic development.

Burn repair boost 🔥Oyster mushroom (Pleurotus ostreatus) powder at 1.5 g daily for 21 days helped burned rats maintain healthier protein levels, lower inflammation signals, and rebuild more collagen in damaged skin. Researchers identified 109 natural compounds in the mushroom, including amino acids, ergothioneine, choline, and phenolics tied to healing and tissue repair. The strongest effect was improved skin structure, with thicker collagen support and better rebuilding of the damaged tissue matrix.

Everyday mushroom defense 🛡️ Button mushroom (Agaricus bisporus) extracts showed stronger antioxidant activity than oyster mushroom (Pleurotus ostreatus), helping fight unstable molecules linked to cell damage and aging. Scientists found natural compounds like gallic acid, caffeic acid, and mannitol that help protect food quality and slow oxidation. Adding just 2% button mushroom extract to broth greatly boosted antioxidant power without changing the taste or savory flavor.

PSILOCYBIN & LEGISLATION

Addiction treatment expansion 💥 Psilocybin at 25 mg/70 kg plus manualized psychotherapy increased cocaine-abstinent days by 29% versus active placebo through 180 days. In 40 adults with cocaine use disorder, psilocybin also raised the likelihood of complete abstinence 18.37× and cut relapse risk by 72%, with no serious adverse events. This is a major psychedelic milestone because cocaine use disorder has no proven medication, and the trial reached underserved participants, including 82.5% Black adults and 65% earning $20,000 or less per year.

Microdosing goes mainstream 📈 Among 1,525 US adults, lifetime microdosing reached 9.4% for cannabis, 5.3% for psilocybin, 4.8% for LSD, and 2.2% for MDMA, equal to an estimated 24.1 million, 13.7 million, 12.4 million, and 5.7 million adults. Psilocybin microdosing was most often reported for recreational reasons at 66%, while microdose use across all substances was more common among people reporting poorer mental health and living in areas with recreational cannabis or decriminalized psychedelics.

Depression response durability 🫂 Psilocybin-assisted therapy produced rapid depression improvements within days to weeks across major depressive disorder trials, including 54% remission at day 14 in one 52-person trial and significant benefit through 43 days in a 104-person trial. Longer follow-up showed 75% response and 58% remission at 12 months in one MDD cohort, while treatment-resistant depression data showed the clearest controlled signal at 25 mg, including 37% response and 29.1% remission at 3 weeks in a 233-person trial. Benefits were strongest when psilocybin was delivered with preparation, supervised dosing, and integration, with mostly transient side effects like anxiety, nausea, headache, dizziness, and brief blood pressure or heart-rate increases.

Psychedelics meet microbiome 🧫 Psilocybin at 3 mg/kg and Psilocybe cubensis extract matched to 3 mg/kg psilocybin/psilocin shifted gut microbiota structure in 18 male Wistar Han rats over 14 days. Both treatments separated from baseline and control microbiota by day 7, with stronger divergence by day 14 and the largest shift in the pure psilocybin group. This adds a gut-brain-axis layer to psychedelic research, showing that pure psilocybin and whole mushroom extracts can reshape microbial communities differently.

Pain relief signal ⚡ Researchers are testing intravenous psilocybin at 1 mg/kg in rats with long-lasting pain linked to fibromyalgia-like symptoms. The pain model lowered muscle pressure tolerance by up to 30% through day 21, making the rats more sensitive to touch and pressure. Earlier animal research found that a single psilocybin dose reduced pain sensitivity for up to 28 days, raising interest in psychedelic-based treatments for chronic pain.

ECOLOGY & CONSERVATION

Waste into fuel ⛽ Waste left behind from growing oyster mushrooms (Pleurotus ostreatus) was turned into bioethanol fuel using bacteria, enzymes, and leftover mushroom substrate made from sawdust and soybean hulls. The best process produced 7.07 g/L ethanol and boosted fuel output 15 times compared to the untreated version. Since mushroom farms can create 3–5 kg of leftover substrate for every 1 kg of mushrooms grown, this could help turn a huge waste problem into renewable energy.

Forest nutrient switch 🍂Soil fungi helped break down nutrient-rich forest litter 13%–28% faster, but slowed nutrient-poor litter by 19%–20% over 120 days. When leaves and plant debris had more nitrogen, the fungi boosted microbial activity and helped release nutrients back into the soil faster. Trees growing with the fungi also grew 20%–30% larger in the richer litter conditions, showing how fungi help forests recycle nutrients and support plant growth.

Programmable fungal cleanup ♻️ Scientists used siRNA gene silencing to switch off key cleanup enzymes in oyster mushroom (Pleurotus ostreatus), helping map which enzymes break down different pollutants and plant wastes. Turning off the enzyme PoLac2 cut bisphenol A (BPA) degradation by 85.8%, while PoLac10 was more important for breaking down cellulose and wheat straw. The fungal gene-silencing system worked for up to 96 hours and opens the door to designing mushrooms that target specific pollutants, farm waste, and environmental toxins more efficiently.

GROWING & GOURMET

Flavor from feed 🌾Oyster mushroom (Pleurotus ostreatus) mycelia made 52 aroma compounds when grown on amaranth seed and Bambara groundnut media. Amaranth brought out stronger mushroom, green, and fatty flavors, while Bambara pushed the flavor toward malty, nutty, fermented, and lightly floral notes. Both mycelia were high in protein, reaching 35.8%–38.2%, with glutamic and aspartic acids adding natural umami potential for future plant-based foods.

Protein bar mushrooms 🍫Straw mushroom (Volvariella volvacea) hydrolysate raised vegan protein bar protein from 22.10% to 22.83% and more than doubled antioxidant power at the 12% dose. Subcritical water plus Alcalase was chosen as the best practical method because it balanced protein recovery, cost, and antioxidant strength. The bars kept similar firmness and texture, showing mushrooms can add protein and functional compounds to everyday snacks without wrecking the bite.

Lion’s mane coffee ☕ Lion’s mane (Hericium erinaceus) worked in specialty coffee at both 0.5% and 1.0%, with 60 taste testers accepting both versions. The 0.5% version scored slightly higher, but the difference was not statistically meaningful, meaning both kept the coffee’s flavor balance. The mushroom also did not meaningfully change the drink’s soluble solids, pH, acidity, or dark coffee color, making it a practical fit for functional coffee blends.

MUSH MORE

Get shroomer news, stories, and more in your inbox